

# Maria C Cid

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4660023/publications.pdf>

Version: 2024-02-01

166  
papers

20,167  
citations

21215

62  
h-index

12272

138  
g-index

175  
all docs

175  
docs citations

175  
times ranked

13209  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Identification of a shared genetic risk locus for Kawasaki disease and immunoglobulin A vasculitis by a cross-phenotype meta-analysis. <i>Rheumatology</i> , 2022, 61, 1204-1210.  | 0.9  | 7         |
| 2  | Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study. <i>Arthritis and Rheumatology</i> , 2022, 74, 295-306.  | 2.9  | 78        |
| 3  | Response to mepolizumab according to disease manifestations in patients with eosinophilic granulomatosis with polyangiitis. <i>European Journal of Internal Medicine</i> , 2022, 95, 61-66.  | 1.0  | 12        |
| 4  | New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension. <i>Rheumatology</i> , 2022, 61, 2915-2922.  | 0.9  | 24        |
| 5  | Management of nonviral mixed cryoglobulinemia vasculitis refractory to rituximab: Data from a European collaborative study and review of the literature. <i>Autoimmunity Reviews</i> , 2022, 21, 103034.   | 2.5  | 8         |
| 6  | Blocking GM-CSF receptor $\hat{\pm}$ with mavrilimumab reduces infiltrating cells, pro-inflammatory markers and neoangiogenesis in ex vivo cultured arteries from patients with giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 524-536. | 0.5  | 26        |
| 7  | Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 653-661.   | 0.5  | 49        |
| 8  | Association Between Baseline Therapy and Flare Reduction in Mepolizumab-Treated Patients With Hypereosinophilic Syndrome. <i>Frontiers in Immunology</i> , 2022, 13, 840974.   | 2.2  | 3         |
| 9  | The Sound of Interconnectivity; The European Vasculitis Society 2022 Report. <i>Kidney International Reports</i> , 2022, 7, 1745-1757.   | 0.4  | 3         |
| 10 | Methylome and transcriptome profiling of giant cell arteritis monocytes reveals novel pathways involved in disease pathogenesis and molecular response to glucocorticoids. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1290-1300.                          | 0.5  | 20        |
| 11 | A multidisciplinary registry of patients with autoimmune and immune-mediated diseases with symptomatic COVID-19 from a single center. <i>Journal of Autoimmunity</i> , 2021, 117, 102580.  | 3.0  | 23        |
| 12 | The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma. <i>Leukemia</i> , 2021, 35, 2635-2649.  | 3.3  | 32        |
| 13 | Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial. <i>Lancet Rheumatology</i> , The, 2021, 3, e328-e336.  | 2.2  | 52        |
| 14 | An 80-year-old man with headache, orbital pain and elevated ESR: challenges in the diagnosis of a patient with suspected giant cell arteritis. <i>Rheumatology</i> , 2021, 60, iii12-iii14.  | 0.9  | 1         |
| 15 | Prevalence of cardiovascular risk factors, the use of statins and of aspirin in Takayasu Arteritis. <i>Scientific Reports</i> , 2021, 11, 14404.   | 1.6  | 8         |
| 16 | Risks and benefits of tocilizumab monotherapy in giant cell arteritis. <i>Lancet Rheumatology</i> , The, 2021, 3, e606-e607.   | 2.2  | 0         |
| 17 | The COVID-19 pandemic and ANCA-associated vasculitis " reports from the EUVAS meeting and EUVAS education forum. <i>Autoimmunity Reviews</i> , 2021, 20, 102986.   | 2.5  | 25        |
| 18 | Large-vessel vasculitis. <i>Nature Reviews Disease Primers</i> , 2021, 7, 93.  | 18.1 | 74        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Trabecular bone score improves fracture risk assessment in glucocorticoid-induced osteoporosis. <i>Rheumatology</i> , 2020, 59, 1574-1580.  | 0.9 | 47        |
| 20 | 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 19-30.  | 0.5 | 667       |
| 21 | PI3K $\gamma$ inhibition reshapes follicular lymphoma's immune microenvironment cross talk and unleashes the activity of venetoclax. <i>Blood Advances</i> , 2020, 4, 4217-4231.                          | 2.5 | 23        |
| 22 | B5 $\beta$ /PP2A Limits Endothelial Cell Apoptosis During Vascular Remodeling. <i>Circulation Research</i> , 2020, 127, 707-723.  | 2.0 | 24        |
| 23 | British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. <i>Rheumatology</i> , 2020, 59, 487-494.  | 0.9 | 56        |
| 24 | British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. <i>Rheumatology</i> , 2020, 59, e1-e23.  | 0.9 | 128       |
| 25 | Treatment of giant-cell arteritis: from broad spectrum immunosuppressive agents to targeted therapies. <i>Rheumatology</i> , 2020, 59, iii17-iii27.   | 0.9 | 9         |
| 26 | A very late presentation of polymyalgia rheumatica in a patient with giant cell arteritis: recurrence or casual association?. <i>Modern Rheumatology Case Reports</i> , 2019, 3, 130-133.                 | 0.3 | 0         |
| 27 | Usefulness of imaging techniques in the management of giant cell arteritis. <i>Medicina Clínica (English)</i> Tj ETQq1 1 0,784314 0,1 0,08 BT /Ov   | 0.1 | 0         |
| 28 | Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. <i>Nature Communications</i> , 2019, 10, 5120.                             | 5.8 | 160       |
| 29 | 185. GENETIC EVIDENCE OF EOSINOPHIL NUMBER UNDERPINNING PR3-AAV AND PLAUSIBLE HOST GENETIC PREDISPOSITION TO MICROBIAL DRIVERS OF DISEASE. <i>Rheumatology</i> , 2019, 58, .                              | 0.9 | 0         |
| 30 | Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 2170-2177. | 1.5 | 82        |
| 31 | Glucocorticoid Dosages and Acute Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab. <i>Arthritis and Rheumatology</i> , 2019, 71, 1329-1338.                       | 2.9 | 74        |
| 32 | Utilidad de las técnicas de imagen en la valoración de la arteritis de células gigantes. <i>Medicina Clínica</i> , 2019, 152, 495-501.  | 0.3 | 3         |
| 33 | SP0073...DIAGNOSIS OF GASTROINTESTINAL VASCULITIS. , 2019, , .  |     | 0         |
| 34 | FRI0487...UTILITY OF TRABECULAR BONE SCORE(TBS) FOR FRACTURE RISK ASSESSMENT IN GLUCOCORTICOID-INDUCED OSTEOPOROSIS. , 2019, , .  |     | 2         |
| 35 | THU0008...GM-CSF PATHWAY SIGNATURE IDENTIFIED IN TEMPORAL ARTERY BIOPSIES OF PATIENTS WITH GIANT CELL ARTERITIS. , 2019, , .  |     | 8         |
| 36 | FRI0466...RISK FACTORS ASSOCIATED WITH THE DEVELOPMENT OF FRACTURES IN GLUCOCORTICOID TREATED PATIENTS. THE ROLE OF HYPOGONADISM. , 2019, , .   |     | 0         |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 37 | FRI0284â€¦RESULTS OF A SYSTEMATIC LITERATURE REVIEW INFORMING THE 2018 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF LARGE VESSEL VASCULITIS: EVIDENCE TO GUIDE THE MANAGEMENT OF GIANT CELL ARTERITIS. , 2019, , .                            |      | 1         |
| 38 | THU0286â€¦MANAGEMENT OF TAKAYASU ARTERITIS: A SYSTEMATIC LITERATURE REVIEW INFORMING THE 2018 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF LARGE VESSEL VASCULITIS. , 2019, , .   |      | 2         |
| 39 | Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 399-405.   | 0.5  | 165       |
| 40 | HIV-associated vasculitis. Part II: histologic and angiographic diagnostic reconfirmation after an uncontrolled HIV infection and fatal outcome. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 117, 151-152.                              | 0.4  | 1         |
| 41 | Biological treatments in giant cell arteritis & Takayasu arteritis. <i>European Journal of Internal Medicine</i> , 2018, 50, 12-19.  | 1.0  | 30        |
| 42 | A TNFSF13B functional variant is not involved in systemic sclerosis and giant cell arteritis susceptibility. <i>PLoS ONE</i> , 2018, 13, e0209343.   | 1.1  | 3         |
| 43 | Expression and Function of IL12/23 Related Cytokine Subunits (p35, p40, and p19) in Giant-Cell Arteritis Lesions: Contribution of p40 to Th1- and Th17-Mediated Inflammatory Pathways. <i>Frontiers in Immunology</i> , 2018, 9, 809.                      | 2.2  | 33        |
| 44 | Pathogenesis of giant-cell arteritis: how targeted therapies are influencing our understanding of the mechanisms involved. <i>Rheumatology</i> , 2018, 57, ii51-ii62.  | 0.9  | 32        |
| 45 | Characterization of isolated retinal vasculitis. Analysis of a cohort from a single center and literature review. <i>Autoimmunity Reviews</i> , 2017, 16, 237-243.   | 2.5  | 25        |
| 46 | Analysis of the common genetic component of large-vessel vasculitides through a meta-ImmunoChip strategy. <i>Scientific Reports</i> , 2017, 7, 43953.  | 1.6  | 52        |
| 47 | Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. <i>New England Journal of Medicine</i> , 2017, 376, 1921-1932.   | 13.9 | 682       |
| 48 | SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma. <i>Blood</i> , 2017, 130, 501-513.   | 0.6  | 90        |
| 49 | Endothelin-1 promotes vascular smooth muscle cell migration across the artery wall: a mechanism contributing to vascular remodelling and intimal hyperplasia in giant-cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1624-1634.       | 0.5  | 67        |
| 50 | A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. <i>American Journal of Human Genetics</i> , 2017, 100, 64-74.   | 2.6  | 78        |
| 51 | The European Vasculitis Society 2016 Meeting Report. <i>Kidney International Reports</i> , 2017, 2, 1018-1031.   | 0.4  | 21        |
| 52 | Trial of Tocilizumab in Giant-Cell Arteritis. <i>New England Journal of Medicine</i> , 2017, 377, 317-328.   | 13.9 | 974       |
| 53 | Newly diagnosed vs. relapsing giant cell arteritis: Baseline data from the GiACTA trial. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, 657-664.  | 1.6  | 62        |
| 54 | Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibodyâ€¦associated vasculitis. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1684-1687.e10. | 1.5  | 22        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Virologic, Clinical, and Immune Response Outcomes of Patients With Hepatitis C Virus-Associated Cryoglobulinemia Treated With Direct-Acting Antivirals. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 575-583.e1.                                   | 2.4 | 99        |
| 56 | Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patients. <i>RMD Open</i> , 2017, 3, e000570.                                    | 1.8 | 33        |
| 57 | Occlusive vasculopathy in human immunodeficiency virus (HIV)-associated vasculitis: unusual clinical and imaging course. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 103, 185-188.   | 0.4 | 0         |
| 58 | Description and Validation of Histological Patterns and Proposal of a Dynamic Model of Inflammatory Infiltration in Giant-cell Arteritis. <i>Medicine (United States)</i> , 2016, 95, e2368.  | 0.4 | 55        |
| 59 | The Expanding Role of Imaging in Systemic Vasculitis. <i>Rheumatic Disease Clinics of North America</i> , 2016, 42, 733-751.  | 0.8 | 30        |
| 60 | Identification of IL-23p19 as an endothelial proinflammatory peptide that promotes gp130-STAT3 signaling. <i>Science Signaling</i> , 2016, 9, ra28.   | 1.6 | 44        |
| 61 | Blocking interferon $\gamma$ reduces expression of chemokines CXCL9, CXCL10 and CXCL11 and decreases macrophage infiltration in ex vivo cultured arteries from patients with giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1177-1186. | 0.5 | 89        |
| 62 | Clinical and genetic characterization of the autoinflammatory diseases diagnosed in an adult reference center. <i>Autoimmunity Reviews</i> , 2016, 15, 9-15.  | 2.5 | 62        |
| 63 | Diagnostic clues for giant cell arteritis: Beyond headache and ischemic optic neuritis. <i>Medicina Clínica (English Edition)</i> , 2015, 144, 380-381.   | 0.1 | 0         |
| 64 | Urologic and male genital manifestations of granulomatosis with polyangiitis. <i>Autoimmunity Reviews</i> , 2015, 14, 897-902.  | 2.5 | 43        |
| 65 | 2015 Recommendations for the Management of Polymyalgia Rheumatica: A European League Against Rheumatism/American College of Rheumatology Collaborative Initiative. <i>Arthritis and Rheumatology</i> , 2015, 67, 2569-2580.                                       | 2.9 | 146       |
| 66 | Imaging in systemic vasculitis. <i>Current Opinion in Rheumatology</i> , 2015, 27, 53-62.   | 2.0 | 49        |
| 67 | A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility. <i>American Journal of Human Genetics</i> , 2015, 96, 565-580.  | 2.6 | 144       |
| 68 | Effect of Glucocorticoid Treatment on Computed Tomography Angiography Detected Large-Vessel Inflammation in Giant-Cell Arteritis. A Prospective, Longitudinal Study. <i>Medicine (United States)</i> , 2015, 94, e486.  | 0.4 | 78        |
| 69 | Sustained Remission: An Unmet Need in Patients with Giant-cell Arteritis. <i>Journal of Rheumatology</i> , 2015, 42, 1081-1082.   | 1.0 | 2         |
| 70 | Evaluation of Aortic Inflammation Using Computed Tomographic Angiography: Vasculitis, Atherosclerosis, or Both. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 415-416.  | 1.3 | 3         |
| 71 | 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1799-1807.                                 | 0.5 | 220       |
| 72 | Advances in the Diagnosis of Large Vessel Vasculitis. <i>Rheumatic Disease Clinics of North America</i> , 2015, 41, 125-140.  | 0.8 | 15        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | Influence of the <i>IL17A</i> locus in giant cell arteritis susceptibility. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1742-1745.  | 0.5 | 36        |
| 74 | 3. Pathogenesis of giant cell arteritis. <i>Rheumatology</i> , 2014, 53, i2-i3.   | 0.9 | 5         |
| 75 | Authors'™ response to the eLetter by Moisevet al. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, e71-e71.  | 0.5 | 0         |
| 76 | Prospective long term follow-up of a cohort of patients with giant cell arteritis screened for aortic structural damage (aneurysm or dilatation). <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1826-1832.  | 0.5 | 103       |
| 77 | New insights into the molecular basis of systemic vasculitis. <i>Nature Reviews Rheumatology</i> , 2014, 10, 323-324.   | 3.5 | 0         |
| 78 | Treatment with angiotensin II receptor blockers is associated with prolonged relapse-free survival, lower relapse rate, and corticosteroid-sparing effect in patients with giant cell arteritis. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 772-777. | 1.6 | 28        |
| 79 | Diagnosis and classification of polyarteritis nodosa. <i>Journal of Autoimmunity</i> , 2014, 48-49, 84-89.  | 3.0 | 189       |
| 80 | Scalp Necrosis in Giant Cell Arteritis. <i>Mayo Clinic Proceedings</i> , 2014, 89, e99.   | 1.4 | 1         |
| 81 | Changes in biomarkers after therapeutic intervention in temporal arteries cultured in Matrigel: a new model for preclinical studies in giant-cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 616-623.   | 0.5 | 68        |
| 82 | Positron emission tomography assessment of large vessel inflammation in patients with newly diagnosed, biopsy-proven giant cell arteritis: a prospective, case-control study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1388-1392.                      | 0.5 | 148       |
| 83 | SOX11 promotes tumor angiogenesis through transcriptional regulation of PDGFA in mantle cell lymphoma. <i>Blood</i> , 2014, 124, 2235-2247.   | 0.6 | 94        |
| 84 | Relapses in Patients With Giant Cell Arteritis. <i>Medicine (United States)</i> , 2014, 93, 194-201.  | 0.4 | 158       |
| 85 | A Candidate Gene Approach Identifies an <i>IL33</i> Genetic Variant as a Novel Genetic Risk Factor for GCA. <i>PLoS ONE</i> , 2014, 9, e113476.   | 1.1 | 17        |
| 86 | 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. <i>Arthritis and Rheumatism</i> , 2013, 65, 1-11.   | 6.7 | 4,839     |
| 87 | Evidence of association of the <i>NLRP1</i> gene with giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 628-630.  | 0.5 | 23        |
| 88 | Early improvement of radiological signs of large-vessel inflammation in giant cell arteritis upon glucocorticoid treatment. <i>Rheumatology</i> , 2013, 52, 1335-1336.  | 0.9 | 9         |
| 89 | Identification of the <i>PTPN22</i> functional variant R620W as susceptibility genetic factor for giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1882-1886.  | 0.5 | 51        |
| 90 | Functionally Relevant Treg Cells Are Present in Giant Cell Arteritis Lesions: Comment on the Article by Samson et al. <i>Arthritis and Rheumatism</i> , 2013, 65, 1133-1134.  | 6.7 | 1         |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 91  | Increased IL-17A expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1481-1487.  | 0.5  | 96        |
| 92  | Life-Threatening Cryoglobulinemic Patients With Hepatitis C. <i>Medicine (United States)</i> , 2013, 92, 273-284.  | 0.4  | 69        |
| 93  | 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 484-492.                                      | 0.5  | 451       |
| 94  | B lymphocytes may play a significant role in large-vessel vasculitis. <i>International Journal of Clinical Rheumatology</i> , 2012, 7, 475-477.  | 0.3  | 2         |
| 95  | The Search for Genetic Links in ANCA-Associated Vasculitis and Its Variants. <i>New England Journal of Medicine</i> , 2012, 367, 271-273.  | 13.9 | 4         |
| 96  | Association of NOS2 and potential effect of VEGF, IL6, CCL2 and IL1RN polymorphisms and haplotypes on susceptibility to GCA—a simultaneous study of 130 potentially functional SNPs in 14 candidate genes. <i>Rheumatology</i> , 2012, 51, 841-851.                    | 0.9  | 38        |
| 97  | Large vessel involvement in biopsy-proven giant cell arteritis: prospective study in 40 newly diagnosed patients using CT angiography. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1170-1176.  | 0.5  | 300       |
| 98  | The cryoglobulinaemias. <i>Lancet</i> , The, 2012, 379, 348-360.   | 6.3  | 460       |
| 99  | Patient-reported Outcomes in Polymyalgia Rheumatica. <i>Journal of Rheumatology</i> , 2012, 39, 795-803.   | 1.0  | 64        |
| 100 | Selective up-regulation of the soluble pattern recognition receptor pentraxin 3 and of vascular endothelial growth factor in giant cell arteritis: Relevance for recent optic nerve ischemia. <i>Arthritis and Rheumatism</i> , 2012, 64, 854-865.                     | 6.7  | 89        |
| 101 | 2012 Provisional classification criteria for polymyalgia rheumatica: A European League Against Rheumatism/American College of Rheumatology collaborative initiative. <i>Arthritis and Rheumatism</i> , 2012, 64, 943-954.  | 6.7  | 273       |
| 102 | The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 344-353.   | 3.3  | 182       |
| 103 | Type 1 autoimmune hepatitis in a patient with microscopic polyangiitis: challenges in diagnosis and treatment. <i>Medicina Clínica</i> , 2011, 136, 345-348.   | 0.3  | 0         |
| 104 | Central Nervous System Vasculitis: Still More Questions than Answers. <i>Current Neuropharmacology</i> , 2011, 9, 437-448.   | 1.4  | 64        |
| 105 | Treatment of Large Vessel Vasculitis. <i>Current Immunology Reviews</i> , 2011, 7, 435-442.  | 1.2  | 7         |
| 106 | Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis—a prospective longitudinal study. <i>Rheumatology</i> , 2011, 50, 2061-2070.   | 0.9  | 97        |
| 107 | Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor $\alpha$ and Tj ETQq1 1 0.784314 rgBT /Overlock 10<br>Research, 2010, 62, 835-841.  | 1.5  | 75        |
| 108 | Increased expression of the endothelin system in arterial lesions from patients with giant-cell arteritis: association between elevated plasma endothelin levels and the development of ischaemic events. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 434-442. | 0.5  | 59        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 109 | Thalidomide decreases gelatinase production by malignant B lymphoid cell lines through disruption of multiple integrin-mediated signaling pathways. <i>Haematologica</i> , 2010, 95, 456-463.   | 1.7 | 16        |
| 110 | EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1744-1750.  | 0.5 | 139       |
| 111 | Treatment of Polymyalgia Rheumatica. <i>Archives of Internal Medicine</i> , 2009, 169, 1839.  | 4.3 | 104       |
| 112 | Small-vessel vasculitis surrounding an uninfamed temporal artery as a diagnostic criterion for polymyalgia rheumatica: Comment on the article by Chatelain et al. <i>Arthritis and Rheumatism</i> , 2009, 60, 2853-2854.                              | 6.7 | 2         |
| 113 | The spectrum of vascular involvement in giant-cell arteritis: clinical consequences of detrimental vascular remodelling at different sites. <i>Apmis</i> , 2009, 117, 10-20.  | 0.9 | 44        |
| 114 | EULAR recommendations for the management of primary small and medium vessel vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 310-317.  | 0.5 | 889       |
| 115 | EULAR recommendations for the management of large vessel vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 318-323.   | 0.5 | 596       |
| 116 | Development of aortic aneurysm/dilatation during the followup of patients with giant cell arteritis: A cross-sectional screening of fifty-four prospectively followed patients. <i>Arthritis and Rheumatism</i> , 2008, 59, 422-430.                  | 6.7 | 174       |
| 117 | Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents. <i>Cytokine</i> , 2008, 41, 244-253.   | 1.4 | 41        |
| 118 | Imatinib mesylate inhibits in vitro and ex vivo biological responses related to vascular occlusion in giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 1581-1588.  | 0.5 | 71        |
| 119 | Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 1004-1010.        | 0.5 | 343       |
| 120 | Systemic vasculitis: still a long and winding road. <i>Current Opinion in Rheumatology</i> , 2008, 20, 1-2.   | 2.0 | 2         |
| 121 | How Is Infliximab Harmful?. <i>Annals of Internal Medicine</i> , 2008, 148, 166.  | 2.0 | 1         |
| 122 | Gelatinase expression and proteolytic activity in giant-cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1429-1435.  | 0.5 | 76        |
| 123 | Genetics of Carney Triad: Recurrent Losses at Chromosome 1 but Lack of Germline Mutations in Genes Associated with Paragangliomas and Gastrointestinal Stromal Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 2938-2943. | 1.8 | 141       |
| 124 | Infliximab for Maintenance of Glucocorticosteroid-Induced Remission of Giant Cell Arteritis. <i>Annals of Internal Medicine</i> , 2007, 146, 621.   | 2.0 | 491       |
| 125 | Development of Ischemic Complications in Patients With Giant Cell Arteritis Presenting With Apparently Isolated Polymyalgia Rheumatica. <i>Medicine (United States)</i> , 2007, 86, 233-241.  | 0.4 | 38        |
| 126 | Five Clinical Conundrums in the Management of Giant Cell Arteritis. <i>Rheumatic Disease Clinics of North America</i> , 2007, 33, 819-834.  | 0.8 | 26        |



| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 127 | Sustained spontaneous clinical remission in giant cell arteritis: Report of two cases with long-term followup. <i>Arthritis and Rheumatism</i> , 2006, 55, 160-162.   | 6.7  | 17        |
| 128 | Association between increased CCL2 (MCP-1) expression in lesions and persistence of disease activity in giant-cell arteritis*. <i>Rheumatology</i> , 2006, 45, 1356-1363.   | 0.9  | 64        |
| 129 | Stimulatory Autoantibodies to the PDGF Receptor in Scleroderma. <i>New England Journal of Medicine</i> , 2006, 355, 1278-1280.  | 13.9 | 8         |
| 130 | Dual function of focal adhesion kinase in regulating integrin $\alpha$ -induced MMP $\alpha$ 2 and MMP $\alpha$ 9 release by human T lymphoid cells. <i>FASEB Journal</i> , 2005, 19, 1875-1877.  | 0.2  | 46        |
| 131 | Endothelial cells, antineutrophil cytoplasmic antibodies, and cytokines in the pathogenesis of systemic vasculitis. <i>Current Rheumatology Reports</i> , 2004, 6, 184-194.   | 2.1  | 43        |
| 132 | Early recruitment of phagocytes contributes to the vascular inflammation of giant cell arteritis. <i>Journal of Pathology</i> , 2004, 204, 311-316.   | 2.1  | 88        |
| 133 | Antiangiogenic effects of anti-tumor necrosis factor $\alpha$ therapy with infliximab in psoriatic arthritis. <i>Arthritis and Rheumatism</i> , 2004, 50, 1636-1641.  | 6.7  | 137       |
| 134 | Treatment with statins does not exhibit a clinically relevant corticosteroid-sparing effect in patients with giant cell arteritis. <i>Arthritis and Rheumatism</i> , 2004, 51, 674-678.   | 6.7  | 48        |
| 135 | Response to thalidomide in multiple myeloma: impact of angiogenic factors. <i>Cytokine</i> , 2004, 26, 145-148.   | 1.4  | 34        |
| 136 | Extramedullary multiple myeloma escapes the effect of thalidomide. <i>Haematologica</i> , 2004, 89, 832-6.  | 1.7  | 100       |
| 137 | Domains of health-related quality of life important to patients with giant cell arteritis. <i>Arthritis and Rheumatism</i> , 2003, 49, 819-825.   | 6.7  | 35        |
| 138 | Tissue production of pro-inflammatory cytokines (IL-1 $\alpha$ , TNF $\alpha$ and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. <i>British Journal of Rheumatology</i> , 2003, 43, 294-301. | 2.5  | 237       |
| 139 | Elevated Production of Interleukin-6 Is Associated With a Lower Incidence of Disease-Related Ischemic Events in Patients With Giant-Cell Arteritis. <i>Circulation</i> , 2003, 107, 2428-2434.  | 1.6  | 169       |
| 140 | Tissue and Serum Angiogenic Activity Is Associated With Low Prevalence of Ischemic Complications in Patients With Giant-Cell Arteritis. <i>Circulation</i> , 2002, 106, 1664-1671.  | 1.6  | 99        |
| 141 | A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. <i>Arthritis and Rheumatism</i> , 2002, 46, 1309-1318.   | 6.7  | 480       |
| 142 | A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. <i>Arthritis and Rheumatism</i> , 2002, 47, 29-35.  | 6.7  | 127       |
| 143 | Estrogens and the Vascular Endothelium. <i>Annals of the New York Academy of Sciences</i> , 2002, 966, 143-157.   | 1.8  | 120       |
| 144 | Endothelial cell biology, perivascular inflammation, and vasculitis.. <i>Cleveland Clinic Journal of Medicine</i> , 2002, 69, SII45-SII45.  | 0.6  | 21        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 145 | Small-vessel vasculitis surrounding a spared temporal artery: Clinical and pathologic findings in a series of twenty-eight patients. <i>Arthritis and Rheumatism</i> , 2001, 44, 1387-1395.   | 6.7 | 105       |
| 146 | Tissue targeting and disease patterns in systemic vasculitis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2001, 15, 259-279.   | 1.4 | 13        |
| 147 | Cell adhesion molecules in the development of inflammatory infiltrates in giant cell arteritis: Inflammation-induced angiogenesis as the preferential site of leukocyte-endothelial cell interactions. <i>Arthritis and Rheumatism</i> , 2000, 43, 184-194.                     | 6.7 | 128       |
| 148 | Fibronectin Upregulates Gelatinase B (MMP-9) and Induces Coordinated Expression of Gelatinase A (MMP-2) and Its Activator MT1-MMP (MMP-14) by Human T Lymphocyte Cell Lines. A Process Repressed Through RAS/MAP Kinase Signaling Pathways. <i>Blood</i> , 1999, 94, 2754-2766. | 0.6 | 177       |
| 149 | Endothelial Cell Activation in Muscle Biopsy Samples Is Related to Clinical Severity in Human Cerebral Malaria. <i>Journal of Infectious Diseases</i> , 1999, 179, 475-483.   | 1.9 | 23        |
| 150 | Estradiol enhances endothelial cell interactions with extracellular matrix proteins via an increase in integrin expression and function. <i>Angiogenesis</i> , 1999, 3, 271-280.  | 3.7 | 34        |
| 151 | Interferon- $\gamma$ may exacerbate cryoglobulinemia-related ischemic manifestations: An adverse effect potentially related to its anti-angiogenic activity. <i>Arthritis and Rheumatism</i> , 1999, 42, 1051-1055.   | 6.7 | 68        |
| 152 | Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. <i>Arthritis and Rheumatism</i> , 1998, 41, 26-32.   | 6.7 | 255       |
| 153 | Dynamic pattern of endothelial cell adhesion molecule expression in muscle and perineural vessels from patients with classic polyarteritis nodosa. <i>Arthritis and Rheumatism</i> , 1998, 41, 435-444.   | 6.7 | 56        |
| 154 | Preparation of Endothelial Cells. <i>Current Protocols in Cell Biology</i> , 1998, 00, Unit 2.3.  | 2.3 | 4         |
| 155 | Large vessel vasculitides. <i>Current Opinion in Rheumatology</i> , 1998, 10, 18-28.  | 2.0 | 78        |
| 156 | T-cell population of primary and secondary cutaneous B-cell lymphomas does not express the cutaneous lymphocyte-associated antigen (CLA). <i>Archives of Dermatological Research</i> , 1997, 289, 327-330.  | 1.1 | 5         |
| 157 | New developments in the pathogenesis of systemic vasculitis. <i>Current Opinion in Rheumatology</i> , 1996, 8, 1-11.  | 2.0 | 51        |
| 158 | OESTROGEN AND ENDOTHELIAL CELL ANGIOGENIC ACTIVITY. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1996, 23, 247-250.   | 0.9 | 36        |
| 159 | Expression of an Estrogen Receptor by Human Coronary Artery and Umbilical Vein Endothelial Cells. <i>Circulation</i> , 1996, 94, 1402-1407.   | 1.6 | 172       |
| 160 | Membrane Attack Complex Deposits in Cutaneous Lesions of Dermatomyositis. <i>Archives of Dermatology</i> , 1995, 131, 1386.   | 1.7 | 55        |
| 161 | Estrogen Promotes Angiogenic Activity in Human Umbilical Vein Endothelial Cells In Vitro and in a Murine Model. <i>Circulation</i> , 1995, 91, 755-763.   | 1.6 | 382       |
| 162 | Signaling through CD50 (ICAM-3) stimulates T lymphocyte binding to human umbilical vein endothelial cells and extracellular matrix proteins via an increase in $\beta$ 1 and $\beta$ 2 integrin function. <i>European Journal of Immunology</i> , 1994, 24, 1377-1382.          | 1.6 | 50        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 163 | Immunohistochemical characterization of inflammatory cells and immunologic activation markers in muscle and nerve biopsy specimens from patients with systemic polyarteritis nodosa. <i>Arthritis and Rheumatism</i> , 1994, 37, 1055-1061. | 6.7 | 67        |
| 164 | Malignant histiocytosis as a fatal complication of systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1991, 34, 1557-1559.   | 6.7 | 1         |
| 165 | Giant-Cell Arteritis Presenting with Ipsilateral Hemiplegia and Lateral Medullary Syndrome. <i>European Neurology</i> , 1989, 29, 266-268.  | 0.6 | 23        |
| 166 | Recurrent Arterial Thrombosis in a Patient with Giant-cell Arteritis and Raised Anticardiolipin Antibody Levels. <i>Rheumatology</i> , 1988, 27, 164-165.   | 0.9 | 21        |